Comerica Bank Raises Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Comerica Bank increased its stake in Alnylam Pharmaceuticals by 23.3%, owning 17,253 shares valued at approximately $4.66 million as of the end of Q1.
• Alnylam's quarterly earnings surpassed expectations, reporting $0.32 EPS and $773.69 million in revenue, demonstrating a year-over-year revenue increase of 17.3%.
• Insider transactions indicate significant selling activity, with executives selling shares totaling over $31 million in the past three months.

Comerica Bank increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 23.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,253 shares of the biopharmaceutical company's stock after acquiring an additional 3,262 shares during the period. Comerica Bank's holdings in Alnylam Pharmaceuticals were worth $4,659,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 2.5% in the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock worth $3,525,544,000 after acquiring an additional 323,206 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in Alnylam Pharmaceuticals by 0.8% in the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock worth $1,192,988,000 after acquiring an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Alnylam Pharmaceuticals by 5.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after acquiring an additional 185,783 shares in the last quarter. American Century Companies Inc. grew its position in Alnylam Pharmaceuticals by 9.8% in the first quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company's stock worth $475,353,000 after acquiring an additional 156,411 shares in the last quarter. Finally, Groupama Asset Managment grew its position in Alnylam Pharmaceuticals by 0.8% in the first quarter. Groupama Asset Managment now owns 1,540,139 shares of the biopharmaceutical company's stock worth $415,868,000 after acquiring an additional 11,689 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on ALNY. Morgan Stanley raised their price objective on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Piper Sandler raised their price objective on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. JPMorgan Chase & Co. raised their price objective on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Finally, Chardan Capital raised their price objective on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Twenty-two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $412.79.

Alnylam Pharmaceuticals Trading Up 1.4%

Shares of Alnylam Pharmaceuticals stock traded up $6.11 on Thursday, hitting $453.54. 714,264 shares of the company traded hands, compared to its average volume of 1,087,238. The stock's 50 day moving average price is $384.89 and its 200-day moving average price is $307.91. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $469.81. The company has a market cap of $59.45 billion, a PE ratio of -183.62 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. During the same quarter in the previous year, the firm posted ($0.13) earnings per share. The company's revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 2,274 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the transaction, the executive vice president directly owned 50,121 shares of the company's stock, valued at $22,718,345.67. This trade represents a 4.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total transaction of $666,986.55. Following the transaction, the executive vice president directly owned 20,221 shares in the company, valued at approximately $9,269,508.61. The trade was a 6.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,594 shares of company stock valued at $25,551,456 over the last quarter. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.